We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

77 ELEKTRONIKA

Develops, manufactures, and markets fully automated and semi-automated urine analyzers, blood glucose meters, rapid t... read more Featured Products: More products

Download Mobile App





77 Elektronika Showcases Latest Developments in Urinalysis

By LabMedica International staff writers
Posted on 08 Feb 2024
Print article
Image: The new pediatric measurement mode of LabUMat 2 and UriSed 3 PRO demonstrated at Medlab Middle East 2024 (Photo courtesy of 77 Elektronika)
Image: The new pediatric measurement mode of LabUMat 2 and UriSed 3 PRO demonstrated at Medlab Middle East 2024 (Photo courtesy of 77 Elektronika)

At Medlab Middle East 2024, 77 Elektronika (Budapest, Hungary) is demonstrating how its high-end urinalysis products can boost laboratory efficiency.

77 Elektronika is showcasing its full product range, including its latest developments in urinalysis, such as the new pediatric measurement mode of LabUMat 2 and UriSed 3 PRO or the brand new research use only (RUO) feature of the UriSed mini device. Urine sediment analysis is very sensitive to inhomogeneous particle distribution in the sample: some urine sediment particles subside quickly and hence, proper mixing is crucial to obtain reliable results. 77 Elektronika has implemented sample level adaptive mixing procedure into its fully automated UriSed technology instruments, the UriSed 2 and UriSed 3 PRO. During sample mixing some urine is aspirated from the test tube and pushed back again. This “sip and spit” mixing is repeated to make sure that all particles are homogenized. This standardized method provides consistent results quickly and effectively.

Visitors to the 77 Elektronika booth at Medlab Middle East 2024 can experience UriSed Technology which offers a premium category solution for sediment analysis, providing high-resolution whole-view field microscopic images in an automatic and reproducible way. The goal of UriSed Technology is to make urinary sediment analysis faster, more reliable, and more operator-independent, eliminating the need for manual microscopy while adhering to gold standard guidelines. With UriSed technology, laboratories can achieve accurate and dependable results in just a fraction of the time it takes with traditional methods. The technology provides a detailed analysis of urine samples, detecting red and white blood cells, epithelial cells, bacteria, and other microscopic elements. This makes it an essential tool for diagnosing various medical conditions, including urinary tract infections, kidney diseases, and many more. The fully automated UriSed 3 PRO urine sediment analyzer provides automatic and reproducible results, ensuring that each sample is analyzed with the same precision and accuracy. Also on display at the event is the UriSed mini device which now comes with the brand new feature of Body Fluid Measurement mode which is available only for RUO mode and not for diagnostic purposes. The two measurement phases of stained and unstained samples enable a wider range of sample analysis that includes various body fluid types.

Related Links:
77 Elektronika

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
MEDLAB 2024
Copyright © 2000-2025 Globetech Media. All rights reserved.